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Abstract Injection drug users (IDUs) may be denied
purchase of sterile syringes even where purchase without a
prescription is legal. This study examined barriers to over-
the-counter (OTC) syringe purchase among IDUs in
Tijuana, Mexico. A quantitative survey and subsequent
focus groups were used to quantify barriers to purchase,
identify their correlates and provide in-depth exploration of
syringe purchase experiences. Of 627 IDUs, 81% pur-
chased a syringe in the past 6 months and 16% were
refused or overcharged. Factors independently associated
with refusal/overcharging were homelessness, receptive
syringe sharing, [5 uses per syringe, and number of life-
time abscesses. Few pharmacies sold syringes to IDUs,
who adapted by limiting purchase attempts to pharmacies
known to sell syringes consistently. Failed purchases
occurred when drug withdrawal required purchase at unu-
sual times or locations, often following release from jail.
IDUs reported syringe sharing, syringe reuse, and search-
ing through unsecured medical waste for syringes in
response to failed purchase attempts. Interventions to
expand OTC syringe sales to IDUs, particularly near
detention facilities, will facilitate safer injection practices.
Keywords Injection drug use  Pharmacies 
Syringe access  Syringe sharing  Mexico
Introduction
Legal barriers that restrict pharmacy-based syringe sales
constitute a structural barrier to HIV prevention [1]. In the
United States, where prescription laws and regulations vary
by state, research has shown that eliminating the need for a
prescription is associated with increased syringe access and
decreased sharing among injection drug users (IDUs). For
example, IDUs in Connecticut were more likely to report
pharmacy purchase of syringes (78 vs. 19%) and less likely
to report syringe sharing (31 vs. 52%) following repeal of
syringe prescription laws in 1992 [2]. In Minnesota, IDUs
were almost three times more likely to purchase syringes at
a pharmacy and 33% less likely to report syringe sharing
after the state enacted a law allowing non-prescription
pharmacy sales of syringes [3]. Most recently, a New York
study [4] showed that a newly established Expanded Syr-
inge Access Demonstration Project was associated with a
significant increase in the proportion of IDUs who obtained
syringes from pharmacies, and that these IDUs were sig-
nificantly less likely to report receptive syringe sharing.
Even in settings where syringes can be purchased
without a prescription, IDUs face barriers to syringe pur-
chase. Pharmacists and pharmacy staff may still be
unwilling—for a variety of reasons—to sell syringes to
persons they suspect of injection drug use. ‘‘Mystery
shopper’’ studies, in which research staff posing as IDUs
attempt to purchase syringes at pharmacies, have
documented refusal rates of 31–59% in areas where over-
the-counter (OTC) syringe purchase is legal [5–11]. Doc-
umented reasons for refusal include confusion regarding
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prevailing laws and regulations; pharmacists’ attitudes
regarding drug use and drug users; and commercial and
safety considerations, including worries about theft, secu-
rity, and increased drug use and discarded syringes near the
pharmacy [12–20]. These studies establish a need for
interventions that go beyond the ‘‘laws on the books’’ to
address how policies are implemented ‘‘on the street,’’ thus
creating an environment that facilitates safer injection
behaviors [21, 22].
OTC syringe sales are legal in Mexico. Tijuana, a city of
approximately 1.4 million people located in Mexico’s
northwestern corner just across the border from San Diego,
California, is home to *1,500 pharmacies, which histori-
cally have thrived on business from Americans seeking to
purchase relatively inexpensive pharmaceuticals. The
ubiquity of these pharmacies makes them a convenient
source of sterile syringes, which are much needed by local
IDUs. Baja California, the state in which Tijuana is loca-
ted, has the second highest cumulative AIDS incidence in
Mexico [23]. Tijuana is situated on a major drug trafficking
route that brings heroin, methamphetamine and other illicit
drugs to the United States, and is increasingly becoming a
domestic market for illicit drugs. Approximately 10,000
IDUs live in Tijuana and HIV prevalence is 4% among
male IDUs, 10% among female IDUs, and 12% among
female IDUs who also engage in sex work [24–26].
Although HIV prevalence remains somewhat low among
Tijuana’s IDUs syringe sharing is common, with 59%
reporting receptive syringe sharing in the past 6 months
[27]. Hepatitis C prevalence in this population is 96% [28].
Prior qualitative research (‘‘El Cuete Phase I’’) by our
group showed that despite the OTC status of syringes in
Tijuana, some IDUs were refused or overcharged when
they attempted to purchase syringes [29]. We undertook the
current study to: (1) quantify the frequency of refusals and
overcharges reported by IDUs at pharmacies in Tijuana; (2)
triangulate these findings with the El Cuete Phase I quali-
tative findings; (3) identify factors associated with experi-
encing barriers to pharmacy purchase; and (4) provide a
detailed understanding of these correlates within the con-
text of IDUs’ experiences.
Methods
Study Design
This study employed a sequential mixed methods design in
which a cross-sectional quantitative study was conducted
after a small qualitative study to validate the findings of the
latter through convergence or triangulation, and in which the
quantitative study was followed by another qualitative study
to provide a contextual explanation of the quantitative
results [30, 31]. Both studies were approved by the Ethics
Board of the Tijuana General Hospital and the Human
Research Protections Program of the University of Califor-
nia, San Diego. All study participants provided voluntary
informed consent.
Quantitative Data Collection
The quantitative study was nested within a longitudinal
study of behavioral and contextual factors for HIV, syphilis
and TB infection among IDUs in Tijuana, Mexico (‘‘El
Cuete Phase III’’). Eligible IDUs were C18 years old, able
to speak Spanish or English, and reported injecting illicit
drugs in the last month. IDU status was confirmed by
examination of injection stigmata. Overall, 1,056 IDUs
were recruited between April 2006 and April 2007 using
respondent driven sampling (RDS) [32] as previously
described [27]. Briefly, a diverse group of ‘‘seeds’’ (het-
erogeneous by age, gender, and neighborhood) was selec-
ted and given uniquely coded coupons to refer their peers
to the study. Waves of recruitment continued as subjects
returning with coupons were given coupons to recruit
members of their social networks. Recruitment and inter-
views were conducted by indigenous outreach workers
through the use of a modified recreational vehicle and a
storefront office.
At baseline and every 6 months thereafter, El Cuete III
study participants completed an interviewer-administered
survey that included questions on demographics; drug use
and sexual behaviors; geographic locations of residence
and drug use; syringe acquisition and use; injection-related
morbidities (e.g., abscess, overdose); and interactions with
police, which have previously been associated with syringe
acquisition and injection behaviors among IDUs in Tijuana
[33, 34]. The ‘‘Determine’’ rapid HIV antibody test was
used to detect the presence of HIV antibodies (Abbott
Pharmaceuticals, Boston, MA). Reactive samples were
confirmed using an HIV-1 enzyme immunoassay and
immunofluorescence assay. At the second study visit,
conducted during the period October 2006–January 2008,
we added specific questions regarding recent attempts to
purchase syringes at a pharmacy and the outcome of those
attempts. For the purposes of analysis, IDUs who reported
being overcharged and/or refused syringe purchase at a
pharmacy in the past 6 months were categorized as having
experienced barriers to pharmacy-based purchase.
Qualitative Data Collection
Between October 2008 and March 2009, we recruited a
subset of 47 IDUs from El Cuete III to participate in focus
groups designed to provide detailed descriptions of IDUs’
experiences related to pharmacy syringe purchase. Five
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focus groups composed of exclusively male participants
and two composed of female participants were held at the
study’s storefront office and led by a Mexican psychologist
with experience in focus group facilitation. Male focus
group participants were recruited based on their primary
geographic area of drug use; specifically, we identified
three high intensity drug use neighborhoods based on
geographic information collected in the parent study and
each focus group consisted of residents from a single one
of these three neighborhoods to optimize the likelihood of
shared pharmacy experiences. As only 14% of participants
in the parent study were female, female focus group par-
ticipants were purposefully recruited by study outreach
personnel as they tracked participants for regularly sched-
uled El Cuete III follow-up visits.
Focus groups were conducted using a semi-structured
interview guide that was developed based on earlier in-
depth qualitative interviews with IDUs in Tijuana, [29]
results from the Phase III cross-sectional quantitative
study, and a pilot focus group. Discussion topics focused
on how IDUs chose the pharmacies for syringe purchase,
detailed accounts of experiences in attempting to purchase
syringes, descriptions of interactions with pharmacy staff,
and specific barriers to pharmacy syringe purchase. Par-
ticipants were also probed to describe the impact of these
barriers on their injection practices. Each focus group
lasted approximately 1 h and participants were reimbursed
$20 for their time.
Data Analysis
Quantitative data were analyzed by comparing the char-
acteristics of IDUs who experienced barriers to pharmacy
syringe purchase to those who did not, using Wilcoxon
rank-sum tests for continuous variables and Pearson’s chi-
square test for categorical variables. Variables significant at
\0.20 were manually entered into a multiple logistic
regression model to identify factors independently associ-
ated with experiencing barriers to syringe purchase at a
significance level \0.05. The analyses were performed
using Stata statistical software [35]. The RDS recruitment
method requires additional analyses to ensure that results
from the multiple logistic regression model are both gen-
eralizable and valid [32]. The RDS Analysis Tool [36] was
used to assess potential bias introduced by the non-random
selection of seeds and a random effects logistic regression
model using WinBUGS [37] was used to identify effects
that might arise from correlation between recruiters and
recruitees, as previously described [27]. Since results of the
RDS-adjusted and unadjusted models yielded similar esti-
mates, we present the unadjusted model herein.
Focus groups were digitally recorded, transcribed,
translated from Spanish to English by a certified translator,
and reviewed as they became available. An iterative pro-
cess was used whereby questions and clarifications arising
from real-time focus group observation and transcript
review were used to inform facilitation of subsequent focus
groups. Transcripts were double-coded using a descriptive
and thematic approach in accordance with the ‘‘Coding
Consensus, Co-occurrence, and Comparison’’ method and
rooted in grounded theory [38, 39]. An explanatory design
was used to explain or build upon initial quantitative results
[40]. In this instance, themes identified from focus group
transcripts were used to understand why certain charac-
teristics were associated with experiencing barriers to
syringe purchase. For the purposes of this paper, specific
text excerpts were selected from the coded qualitative
transcripts to provide context for the quantitative findings.
Results
Overall, 649 IDUs were administered the Visit 2 survey
instrument of whom 627 (96.6%) responded to the ques-
tions on pharmacy syringe purchase. A majority (82.1%)
was male and median age was 38 years (interquartile range
[IQR]: 33–44). Almost all IDUs (87.5%) reported injecting
daily during the past 6 months; 80.7% reported injecting
heroin alone, 51.3% injected heroin and methamphetamine
together, and 14.2% injected methamphetamine alone. Few
reported injecting cocaine, either alone (0.6%) or in com-
bination with heroin (6.1%) or methamphetamine (1.3%).
More than one-third (39.7%) reported receptive syringe
sharing in the past 6 months.
Barriers to Pharmacy Syringe Purchase—Frequencies
Most IDUs (80.7%) in the quantitative study reported
purchasing a syringe in a pharmacy in the past 6 months;
overall, 71.6% cited pharmacies as their primary source of
syringes. Only 16.0% experienced barriers to pharmacy
syringe purchase, including being refused purchase (7.0%),
being overcharged (1.9%) or both (7.0%).
These findings are in direct contrast to the qualitative
findings in El Cuete Phase I, in which many participants
reported refusal or overcharging when attempting to pur-
chase syringes at pharmacies in Tijuana [29]. These con-
flicting findings can be attributed at least in part to
differences in the time frames covered by the interviews,
i.e., El Cuete Phase I interview questions were not time-
specific while the Phase III interview questions covered
only experiences in the past 6 months. They may also be
attributed in part to different data collection timeframes,
i.e., El Cuete Phase I data was collected in 2004 while El
Cuete Phase III qualitative data were collected between
October 2006 and January 2008. However, another
AIDS Behav (2010) 14:679–687 681
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explanation emerged early on in the focus groups: that
IDUs in Tijuana have partially adapted to the barriers
erected by local pharmacies through a process of identi-
fying one or more pharmacies over time that will sell to
them consistently. Generally, these pharmacies were
identified through word-of-mouth. When IDUs did pur-
chase sterile syringes, they visited these pharmacies almost
exclusively and, in doing so, substantially reduced the
likelihood that they would be refused or overcharged:
Man 1: …we usually buy at one pharmacy in par-
ticular where they never deny [syringes] to us…of
five pharmacies, only one sells them to us and that’s
where we go. But as for the others, we know by logic
that they will not sell them to us there…[so] we don’t
go there.
In general, purchase attempts at pharmacies other than
those regularly patronized occurred only when IDUs found
themselves experiencing withdrawal symptoms at a time
when their usual pharmacy was far away or closed. Pur-
chase attempts at these pharmacies were more likely to
result in refusals or overcharging. Several IDUs noted that
withdrawal symptoms experienced late at night were
especially problematic and led them to attempt syringe
purchase at other pharmacies:
Man 1: [M]any of us struggle to get better and, well,
we have the addiction 24 hours a day and pharmacies
are not open all 24 hours. The pharmacies where we
buy, well, they close early, and many times in the
middle of the night, well, we’re kind of looking [for a
clean syringe] and it can’t be found.
Withdrawal was reportedly common after release from
police detention. IDUs in Tijuana can be held for up to
36 h by police without being charged, and upon release are
anxious to inject heroin to relieve the withdrawal symp-
toms experienced as a result of their detention. The local
detention center is in the neighborhood Veinte de No-
viembre (‘‘La Veinte’’), which is a substantial distance
from the neighborhoods in which most IDUs live, use
drugs and purchase syringes. Several IDUs discussed
experiencing difficulties accessing sterile syringes after
their release. Further complicating the situation is the fact
that they were often released from custody late at night:
Man 2: [O]ne time I left La Veinte around three in the
morning or four and as I was saying it’s very rare for
them to sell to you there…on that side of Veinte de
Noviembre, they don’t sell syringes to you…You
have to send someone who uses, what’s it called?
Insulin…but they don’t sell to you, it’s not easy to get
syringes, and much less at three thirty or almost four
in the morning and so instead I came over
here…close to the hospital there’s a pharmacy that’s
open 24 hours and there they sold it to me for 45
pesos…normally it’s about 5 pesos, 10 pesos.
Barriers to Pharmacy Syringe Purchase—Correlates
and Contexts
Table 1 presents results from the univariate analysis com-
paring characteristics of IDUs who did and did not
encounter barriers to syringe access over the past 6 months.
IDUs who experienced barriers were more likely to be
homeless; to be stimulant users; and to engage in risky
injection behaviors, including syringe sharing and reuse.
They were also significantly more likely to cite pharmacies
as a source of new syringes (94.0 vs. 76.5%, v2 = 15.715,
P \ .001), although less likely to view sterile syringe
acquisition as ‘‘very easy’’ (12.0 vs. 27.4%, v2 = 10.637,
P = .005), and more likely to report recent arrest for syr-
inge possession (20.0 vs. 9.9%, v2 = 8.490, P = .004).
Table 2 shows results of a multiple logistic regression
model that identifies four variables independently associated
with experiencing barriers to pharmacy syringe purchase:
homelessness, receptive syringe sharing, higher number of
uses per syringe, and lifetime number of abscesses.
Homelessness
IDUs who reported homelessness during the past 6 months
were more than twice as likely to report being refused or
overcharged than IDUs who were not homeless (adjusted
odds ratio (AOR) = 2.24; 95% CI: 1.29, 3.89). In the focus
groups, participants did not cite a direct association between
homelessness and barriers to syringe purchase, but referred
frequently to unkempt appearance—often a direct conse-
quence of homelessness—as a perceived reason for being
refused syringes. ‘‘Appearance’’ was variably described as
being influenced by the type and cleanliness of their cloth-
ing, cleanliness of their person, the presence of body odor
and so on, but was almost universally identified by IDUs as a
barrier to sterile syringe purchase at local pharmacies. One
participant recalled an experience where the pharmacy
worker specifically cited his appearance as unacceptable:
Man 2: And once I …went by a pharmacy that was
there by the one in [the Zona Rı´o neighborhood] and I
go in and I say to him, ‘excuse me would you sell me [a
syringe]’ and he just looks at me, it’s a man and he tells
me, ‘Hey’, he says, ‘make this the last time that I sell to
you like with you coming like that. Next time,’ he tells
me, ‘I won’t sell syringes to people like you who come
like that and if you want me to sell you syringes you
have to take a shower and change, you have to look
nice.’
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IDUs generally believed that pharmacists were troubled
by their appearance because it negatively affected the
‘‘image’’ of the pharmacy and thus was bad for business.
However, some participants reported being told by phar-
macists that (despite the legality of OTC syringe sales) they
feared trouble with the police if they were even perceived
Table 1 Factors associated
with barriers to pharmacy
syringe purchasea among IDUs
in Tijuana, Mexico
a Past 6 months
b Test statistic is z-score for
Wilcoxon rank-sum test
Refused/overcharged v2 (P)
Yes % (n = 100) No % (n = 527)
Demographics
Male 82.0 82.2 .002 (.969)
Median age (IQR)b 37 (33–43) 38 (33–44) .397 (.692)
Homelessa 23.0 11.0 10.749 (.001)
Injection drug usea
Heroin alone 70.0 82.7 8.691 (.003)
Methamphetamine alone 13.0 14.4 .139 (.709)
Cocaine alone 3.0 0.2 10.472 (.001)
Heroin and methamphetamine 61.0 49.4 4.502 (.034)
Heroin and cocaine 7.2 5.9 .268 (.605)
Methamphetamine and cocaine 1.0 1.3 .072 (.789)
Injected daily 92.0 86.7 2.188 (.139)
Receptive syringe sharing 52.0 37.2 7.709 (.005)
Distributive syringe sharing 53.0 39.5 6.333 (.012)
Average # uses per syringe [5 54.0 38.5 8.327 (.004)
Syringe acquisitiona
Sources for new syringes
Pharmacy 94.0 76.5 15.715 (\.001)
Syringe exchange program 41.0 35.7 1.029 (.311)
Market 23.0 25.1 .189 (.663)
Ease of clean syringe acquisition




Arrest for possessing new syringe 12.0 8.9 .936 (.333)
Arrest for possessing used syringe 20.0 9.9 8.490 (.004)
Arrest for track marks 18.0 16.1 .214 (.643)
Police caused rushed injection 10.0 5.9 2.332 (.127)
Injection associated morbidities
HIV positive 7.2 5.9 .239 (.625)
Abscess last 6 months 20.0 20.5 .013 (.911)
Abscess ever 48.0 45.5 .205 (.651)
Median # abscesses (lifetime)b 0 (0–3) 0 (0–2) -1.297 (.195)
Table 2 Factors independently
associated with barriers to
pharmacy syringe purchasea
among IDUs in Tijuana, Mexico
a Past 6 months
Adjusted odds ratio
(95% confidence interval)
Homelessa 2.24 (1.29, 3.89)
Receptive syringe sharinga 1.57 (1.01, 2.45)
Average uses per syringe [5a 1.74 (1.11, 2.71)
Number of abscesses (lifetime) 1.02 (1.00, 1.03)
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to be selling syringes to IDUs and were therefore reluctant
to have anyone whose appearance suggested drug use in
their pharmacy.
Receptive Syringe Sharing
In the quantitative study, experiencing barriers to syringe
purchase was independently associated with receptive
syringe sharing (AOR = 1.57; 95% CI: 1.01, 2.45). This
finding is consistent with the results of the El Cuete Phase I
interviews, which found that syringe sharing was a direct
response to experiencing barriers to sterile syringe access.
In the focus groups, participants reported that they com-
monly responded to pharmacy refusals and overcharging
by purchasing or sharing syringes that had already been
used—a practice that placed them at risk of acquiring HIV,
hepatitis C and other blood borne infections. Sources of
used syringes included friends or other users from whom
syringes were borrowed, purchased or traded for a few
drops of the drug:
Man 2: I think that many [pharmacists] think that by
prohibiting the sale of syringes that they are going to
stop the usage of drugs…but what they are doing is
wrong, because of that we have a harder time finding
syringes. We need to use drugs in order to feel well,
since when we are in need of a fix we feel desperate
enough that we don’t care and borrow one from a
friend, since it’s a desperate feeling we just don’t
care…
Others reported using syringes they found in medical
waste when they could not purchase sterile syringes:
Man 1: They didn’t want to sell [a syringe] to me and
I had to go out and look and look for one [and] I
found one of those that have been thrown away.
Man 3: We have even come to the point of also
looking like that in places where they’re used and see
who, where those people are, you know like the Red
Cross and all those places or the hospital or you look
over there in the trash…Many times the need for [a
syringe] makes us go look for them at the clinics
where they throw them away, with the [biohazard]
containers… you just wash them with water.
Still others reported using syringes found in household
trash. The focus groups also included discussions of a
secondary market for syringes in Tijuana, where syringes
gathered through searching medical waste, household trash
and the streets were washed and then resold to fill the gap
left by inadequate sterile syringe supply.
Syringe Reuse and Abscesses
Reusing syringes an average of [5 times was significantly
associated with experiencing barriers to syringe purchase
in the final quantitative model (AOR = 1.74; 95% CI:
1.11, 2.71). Male focus group participants seemed to view
syringe reuse as normative and linked the practice directly
to limited access to sterile syringes, including inability to
purchase syringes from pharmacies:
Man 1: All syringes are for a single use, supposedly,
right. [But] I’ll carry it up to a month, for as long as it
works.
Man 2: For as long as it works, seriously.
Man 3: [Y]ou want to get one and it depends on
where you are, you’re out of the neighborhood and
they won’t sell to you; I mean, so then instead you
just say I’m going to take mine because even though
it’s all messed up, well, they won’t sell to you there.
Male participants also described methods for keeping
reused syringes in use for extended periods of time, which
included sharpening the tip with matches, as well as
describing the direct effects of using a dull syringe on the
injection process:
Man 6: Sometimes, well, the truth is, one syringe,
well, it can last you up to two or three days. Honestly,
by the time you get to use it, it either stops working or
it sticks to you. I mean, the blood clots, and so then
you have to buy another one…
Discussion in the female focus groups focused primarily
on the difficulties posed as a result of syringe reuse, with
women citing their comparatively ‘‘small veins’’ as pre-
senting problems for injecting with reused syringes:
Woman 2: [I] struggle to get my veins, you know, I
just really need a new one and not just one syringe a
day, no, I have to buy up to four syringes a day…-
because of the small veins we have.
Difficulty injecting due to syringe reuse—itself a direct
outcome of limited access to new syringes—can result in
‘‘skin popping’’ and other injection practices that increase
the risk of abscess. Even after controlling for syringe reuse
in our quantitative model, experiencing barriers to phar-
macy syringe purchase was marginally associated with a
higher number of lifetime abscesses (AOR = 1.02; 95%
CI: 1.00, 1.03). In general, while focus group participants
spoke frequently about the fact that syringe sharing put
them at risk of HIV infection, none made a direct con-
nection between reusing syringes and abscess risk until
probed by the facilitator during the last focus group:
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Facilitator: Do you damage your skin because you
don’t have a new syringe? Have you gotten abscesses?
Woman 2: I have gotten abscesses. Look, I have, I
have them all over my arms because many times I’ve
struggled with the syringes even because it doesn’t
have a tip and I don’t get the vein well and since I
suffer from my veins.
At the conclusion of each focus group, the facilitator
asked the participants how having better access to syringes
at pharmacies would affect their lives. While most IDUs
talked about how expanded pharmacy-based syringe access
would help them to avoid syringe sharing and HIV infec-
tion, none cited reductions in reuse or abscesses as a
potential benefit of expanded pharmacy syringe access.
Discussion
Our quantitative study found that a majority of IDUs in
Tijuana used pharmacies as their primary source for new
syringes and few reported being recently refused or over-
charged. These quantitative findings suggest that sterile
syringe access is not a problem in Tijuana; however, they
obscure the process through which IDUs have adapted to
what is in reality a very limited market for syringes. Our
focus groups ascertained that IDUs identified pharmacies (or
more frequently a single pharmacy) that would sell syringes
to them consistently and relied on those pharmacies almost
exclusively, substantially reducing the likelihood of refusal
or overcharging. These findings complement findings from
our previous qualitative work in Tijuana, which documented
barriers to pharmacy-based syringe access but not the sub-
sequent process of adaptation [29]. They also provide a case
study in the value of using multiple methods in HIV pre-
vention research, as the quantitative findings alone would
have provided a highly distorted view of the role of Tijuana
pharmacies in sterile syringe access.
Our qualitative study found that this adaptive approach
to syringe purchase can be easily disturbed, particularly
when withdrawal symptoms necessitate immediate injec-
tion. IDUs described situations in which periods of police
detention or mismanaged dosing led them to urgently seek
a syringe in a location (e.g., near a detention facility) or at a
time of day (e.g., late at night) that deviated from their
usual routine. Efforts to obtain a sterile syringe under these
circumstances were often unsuccessful and led directly to
syringe sharing or reuse. The period immediately following
release from jail or prison has been identified previously as
a high risk time for overdose [41–43]. Our findings suggest
that, where syringe access is limited, the immediate post-
release period is also a high risk time for syringe sharing.
Prioritizing interventions for pharmacies located near
detention facilities could substantially reduce syringe
sharing among IDUs. Expanding access to sterile syringes
late at night, when a majority of pharmacies are closed,
could have a similar effect and warrants interventions
especially targeted towards 24-h pharmacies.
Our examination of correlates and contexts found that
homeless IDUs were more than twice as likely to report
barriers to syringe purchase. Numerous studies have
reported associations between homelessness and high risk
injection behaviors [44–49]. Hypothesized causal pathways
include the need for homeless IDUs to find a discreet place
to inject (e.g., shooting gallery) to avoid police detection,
the need to rush injections in public places, and charac-
teristics of homeless IDUs’ social networks that normalize
syringe sharing. Our focus group findings suggest another
hypothesis: homeless IDUs may have difficulty purchasing
OTC syringes where their right to do so is not enforced.
The unkempt appearance of these IDUs may make them
more identifiable to pharmacy staff as drug users, or may
be viewed as offensive or frightening to other customers
and bad for business, thus increasing the likelihood of
refusal. A recent qualitative study from the United King-
dom similarly documented stigmatization of IDUs based
on housing status and appearance, finding that these IDUs
are stigmatized by both pharmacists and other IDUs [50].
Any interventions designed to improve pharmacy-based
access to sterile syringes in Tijuana will need to include
measures for addressing stigmatization of these highly
marginalized IDUs.
While homelessness increases the likelihood that IDUs
will be refused or overcharged when attempting to pur-
chase syringes, the other correlates we observed were more
likely to occur as a result of encountering these barriers.
Focus group participants made a direct connection between
their inability to purchase sterile syringes and syringe
sharing, which places them at risk of infection with HIV
and other blood borne pathogens. The link between
restrictive pharmacy sales and syringe sharing has been
previously reported [2–4]. Our study adds to this growing
literature on syringe access and injection risk and makes
clear the need for interventions to improve adherence to
OTC syringe purchase laws. Interventions elsewhere have
accomplished this through pharmacist training, information
dissemination, and community outreach [51] and might
serve as models for future interventions in Tijuana.
Among the more disturbing findings from our study is
that IDUs linked restrictive syringe sales practices in
Tijuana with the use of syringes salvaged from medical
waste and household trash. Use of these syringes puts IDUs
at risk of both viral and bacterial infections. Medical waste
disposal at Tijuana clinics and hospitals is governed by laws
similar to those in the U.S. (e.g., the California Medical
Waste Management Act of 1990 [52]). Mexican law [53]
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requires that health facilities dispose of sharps in a puncture-
proof container with a top that can be permanently sealed.
These containers must be kept in a restricted area until they
are picked up for transport to a permitted disposal facility.
The fact that IDUs report salvaging syringes from clinic
waste in Tijuana suggests that adherence to this law may
need stricter enforcement. In contrast, there are no Mexican
laws governing home-based disposal of syringes. Across the
border in California, a law governing disposal of home-
generated sharps didn’t become effective until January 1,
2008, when Senate Bill 1305 closed a loophole in the state’s
Medical Waste Management Act that exempted these sharps
from regulation. Passing a similar law designed to promote
safer disposal of home-generated sharps in Mexico could
reduce the likelihood that IDUs will salvage used syringes
from household trash.
Finally, we found that experiencing barriers to syringe
purchase is associated with higher odds of syringe reuse
and abscesses. While these consequences did not appear to
be as high a priority for IDUs as syringe sharing, which
they linked clearly with HIV infection, abscesses are a
frequent and sometimes serious complication of injection
among IDUs in Tijuana and elsewhere [54–56]. Expanding
OTC syringe access would increase the likelihood of using
a new syringe for every injection.
This study was limited by the fact that we only inter-
viewed IDUs. Subsequent research needs to include inter-
views with pharmacists and pharmacy staff in Tijuana to
fully understand the factors that influence syringe sales
practices and design appropriate interventions. Our studies
were also conducted over a period of approximately 5
years, which may obscure any substantial changes in OTC
syringe sales practices over time.
In summary, we found that pharmacies play an impor-
tant role in meeting the syringe needs of IDUs in Tijuana
but that restrictive sales practices limit the ability of IDUs
to access sterile syringes where, when and in the quantities
needed and lead to syringe sharing and reuse. Pharmacy-
targeted interventions to expand OTC syringe sales in
Tijuana, particularly near detention facilities, would
increase safe injection behaviors and reduce the likelihood
of injection-related infections.
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